12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Stelara ustekinumab: Phase IV data

The open-label, European Phase IV TRANSIT trial in 489 patients with moderate to severe plaque psoriasis who had an inadequate response to methotrexate showed that switching to Stelara was well tolerated regardless of the transition strategy. Specifically, serious adverse events occurred in 8% of patients who discontinued methotrexate treatment and immediately...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >